Antibody Discovery News and Research

RSS

Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center

Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery.

From Thermo Fisher Scientific Inc. 23 Sep 2020

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

CARE consortium launches to accelerate drug discovery and development for COVID-19

CARE a new consortium supported by the Innovative Medicines Initiative public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

19 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Sphere Fluidics 20 Jul 2020

An improved tetravalent antibody blocks SARS-CoV-2 infection

A new study published on the preprint server bioRxiv* in June 2020 shows the potential of a new fusion molecule called a biparatopic protein to inhibit viral interaction with the host cell ACE2 receptor. This could lead to therapeutic applications.

17 Jun 2020

Twist Bioscience and Serimmune collaborate to identify SARS-CoV-2 therapeutic antibody candidates

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Serimmune Inc., a leader in understanding the functional antibody repertoire’s role in human disease, today announced a collaboration to identify and evaluate SARS-CoV-2 therapeutic antibody candidates from Twist libraries.

From Twist Bioscience 10 Jun 2020

New design strategy marks a potential advance in the fight against Alzheimer's disease

Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells - a potential advance in the fight against Alzheimer's disease.

26 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020

Israeli scientists discover monoclonal antibody that neutralizes SARS-CoV-2

Now, in a significant medical breakthrough, Israel's Institute for Biological Research Institute (IIBRI) has wrapped up the development of a potential treatment for the coronavirus disease. The scientists say they have identified an antibody that neutralizes SARS-CoV-2.

5 May 2020

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

Antibody Discovery News and Research

Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

CARE consortium launches to accelerate drug discovery and development for COVID-19

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

An improved tetravalent antibody blocks SARS-CoV-2 infection

Twist Bioscience and Serimmune collaborate to identify SARS-CoV-2 therapeutic antibody candidates

New design strategy marks a potential advance in the fight against Alzheimer's disease

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

OXGENE™ reports third consecutive year of 100% year on year revenue growth

Israeli scientists discover monoclonal antibody that neutralizes SARS-CoV-2

Scientists are developing synthetic COVID-19 antibody to treat sick patients

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis

Berkeley Lights Announces GEPAD to Attack COVID-19 and Other Viruses

Celltrion announces key milestones in its efforts to fight COVID-19

DSI alumni use computational design to quickly discover treatments for COVID-19

Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics

Carterra closes financing round for continued growth of the LSA platform for next generation antibody discovery

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Antibodies eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News